CORRESP Filing
Curanex Pharmaceuticals Inc
Date: Aug. 8, 2025 · CIK: 0002025942 · Accession: 0001493152-25-011762
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282686
Letter
Curanex Pharmaceuticals Inc
Jericho Plaza, Suite 101B
Jericho, NY 11753
August 8, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Technology
F Street N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama and Chris Edward
Re:
Curanex Pharmaceuticals Inc Registration Statement on Form S-1, as amended (the "Registration Statement") File No. 333-282686 Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Act"), Curanex Pharmaceuticals Inc (the "Company") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective at 5:00 p.m. on August 12, 2025, or as soon thereafter as is practicable. In connection with such request, the undersigned hereby acknowledges the following:
1. Should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing.
2. The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing.
3. The Company may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
Curanex
Pharmaceuticals Inc
Show Raw Text
CORRESP 1 filename1.htm Curanex Pharmaceuticals Inc 2 Jericho Plaza, Suite 101B Jericho, NY 11753 August 8, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology 100 F Street N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama and Chris Edward Re: Curanex Pharmaceuticals Inc Registration Statement on Form S-1, as amended (the "Registration Statement") File No. 333-282686 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the "Act"), Curanex Pharmaceuticals Inc (the "Company") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement so that such Registration Statement will become effective at 5:00 p.m. on August 12, 2025, or as soon thereafter as is practicable. In connection with such request, the undersigned hereby acknowledges the following: 1. Should the Securities and Exchange Commission (the "Commission") or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing. 2. The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing. 3. The Company may not assert staff comments or the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, Curanex Pharmaceuticals Inc By: /s/ Jun Liu Jun Liu Chief Executive Officer